What is Tesamorelin? Tesamorelin is a synthetic peptide that mimics the effects of growth hormone-releasing hormone (GHRH), a naturally occurring hormone It stimulates the pituitary gland to produce and release growth hormone (GH). Tesamorelin is FDA-approved under the brand name Egrifta for treating excess abdominal fat (lipodystrophy) in patients with HIV infection, specifically reducing visceral adipose tissue (VAT). 

What are the potential Tesamorelin? Visceral fat reduction: Studies have shown it effectively reduces visceral fat, particularly in individuals with HIV-associated lipodystrophy, and potentially in other populations with metabolic concerns. Improved body composition: May lead to increased lean muscle mass and improved strength. Enhanced recovery: Supports the body's natural ability to repair and rebuild after exercise. Improved sleep quality: May promote deeper and more restful sleep. Potential cardiovascular benefits: Studies suggest it may improve lipid profiles and cardiovascular health.